Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Steward

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Mucosal Immunology|November 21, 2025
Activation status of airway immune cells is a defining feature of severe asthma, regardless of fungal sensitisationEmily L Plumpton, Stefano A P Colombo, Matthew Steward, et al.
ERJ Open Research|March 23, 2023
Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational studyLavanya Raman, Iain Stewart, Shaney L Barratt, et al.
Clinical Immunology (Orlando, Fla.)|April 4, 2024
Identification of connective tissue disease autoantibodies and a novel autoantibody anti-annexin A11 in patients with "idiopathic" interstitial lung diseaseSarah L Tansley, Fionnuala McMorrow, Caroline V Cotton, et al.
Eclinicalmedicine|December 9, 2022
Multi-center evaluation of baseline neutrophil-to-lymphocyte (NLR) ratio as an independent predictor of mortality and clinical risk stratifier in idiopathic pulmonary fibrosisTheresia A Mikolasch, Peter M George, Jagdeep Sahota, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Mucosal Immunology|November 21, 2025
Activation status of airway immune cells is a defining feature of severe asthma, regardless of fungal sensitisationEmily L Plumpton, Stefano A P Colombo, Matthew Steward, et al.
ERJ Open Research|March 23, 2023
Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational studyLavanya Raman, Iain Stewart, Shaney L Barratt, et al.
Clinical Immunology (Orlando, Fla.)|April 4, 2024
Identification of connective tissue disease autoantibodies and a novel autoantibody anti-annexin A11 in patients with "idiopathic" interstitial lung diseaseSarah L Tansley, Fionnuala McMorrow, Caroline V Cotton, et al.
Eclinicalmedicine|December 9, 2022
Multi-center evaluation of baseline neutrophil-to-lymphocyte (NLR) ratio as an independent predictor of mortality and clinical risk stratifier in idiopathic pulmonary fibrosisTheresia A Mikolasch, Peter M George, Jagdeep Sahota, et al.
Pageof 2